Status:
COMPLETED
Lessening Organ Dysfunction With VITamin C - COVID-19
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Lotte & John Hecht Memorial Foundation
Conditions:
Vitamin C
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or pers...
Detailed Description
Background. Research suggests that vitamin C is potentially lifesaving in the intense inflammatory cascade such as that associated with COVID-19. Inflammation and oxidative stress are among the main m...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of COVID-19;
- Admitted to hospital (ward or intensive care unit).
Exclusion
- Receiving or has received vasopressors during the current hospitalization;
- More than 24 hours has elapsed since receipt of non-invasive ventilatory support (high-flow nasal cannula or continuous positive airway pressure or non-invasive ventilation) or invasive mechanical ventilation;
- Patient is expected to be discharged from the hospital in the next 24 hours;
- More than 14 days have elapsed since the commencement of hospital admission with respiratory illness;
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency;
- Known sickle cell anemia
- Pregnancy or breastfeeding;
- Known allergy to vitamin C;
- Known kidney stones within the past 1 year;
- Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;
- Expected death or withdrawal of life-sustaining treatments within 48 hours;
- Previously enrolled in this study;
- Previously enrolled in a trial for which co-enrolment is not allowed (co- enrolment to be determined case by case).
- The trial has broad eligibility criteria and includes all COVID-19 patients admitted to the hospital (e.g. hospital ward or the intensive care unit) who are not receiving vasopressors.
Key Trial Info
Start Date :
August 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2022
Estimated Enrollment :
392 Patients enrolled
Trial Details
Trial ID
NCT04401150
Start Date
August 14 2020
End Date
December 6 2022
Last Update
April 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Center of the CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
2
Research Centre of the CHUS
Sherbrooke, Quebec, Canada, J1H 5N4